<div id="readability-page-1"><p><span>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report)</span> had its price objective raised by analysts at HC Wainwright  from $120.00 to $135.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the biopharmaceutical company's stock. HC Wainwright's price target would indicate a potential upside of 167.86% from the stock's previous close.</p><div><p><span></span><span>Get <strong>Nektar Therapeutics</strong> alerts:</span></p></div><ul><li>3 Bullish Biotech Stocks With Explosive Growth Trends</li></ul><p>Several other brokerages have also weighed in on NKTR. Jefferies Financial Group  reissued a &#34;buy&#34; rating and issued a $121.00 price objective (up previously from $99.00) on shares of Nektar Therapeutics in a report on Monday, November 24th. BTIG Research  restated a &#34;buy&#34; rating and set a $100.00 target price on shares of Nektar Therapeutics in a research report on Friday, September 19th. Citigroup initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, November 26th. They issued a &#34;buy&#34; rating and a $102.00 price target for the company. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Nektar Therapeutics in a report on Monday, December 8th. Finally, Wall Street Zen lowered shares of Nektar Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Sunday, November 16th. Six investment analysts have rated the stock with a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $108.83.</p><p><b>View Our Latest Stock Report on Nektar Therapeutics</b></p><h2>Nektar Therapeutics Stock Performance</h2><ul><li>Biotech Catalyst Alert: NKTR, CDTX &amp; WGS Rallying With Big Gains</li></ul><p>NKTR stock traded down $2.90 during mid-day trading on Tuesday, hitting $50.40. The company had a trading volume of 3,258,306 shares, compared to its average volume of 886,831. The firm has a market cap of $1.03 billion, a PE ratio of -6.32 and a beta of 1.27. Nektar Therapeutics has a 12 month low of $6.45 and a 12 month high of $66.92. The stock's fifty day moving average price is $58.35 and its two-hundred day moving average price is $39.65. </p><p>Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last released its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share for the quarter, beating analysts' consensus estimates of ($2.85) by $1.00. Nektar Therapeutics had a negative net margin of 192.87% and a negative return on equity of 456.53%. The firm had revenue of $11.79 million during the quarter, compared to the consensus estimate of $10.20 million.  Equities analysts anticipate that  Nektar Therapeutics will post -0.72 earnings per share for the current year. </p><h2>Insider Buying and Selling at Nektar Therapeutics</h2><ul><li>Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?</li></ul><p>In related news, CEO Howard W. Robin sold 2,207 shares of the business's stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $54.28, for a total transaction of $119,795.96. Following the transaction, the chief executive officer owned 54,245 shares in the company, valued at $2,944,418.60. The trade was a 3.91% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, insider Mark Andrew Wilson sold 630 shares of the company's stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total value of $34,196.40. Following the transaction, the insider directly owned 21,585 shares of the company's stock, valued at $1,171,633.80. The trade was a 2.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,994 shares of company stock worth $216,794. 3.71% of the stock is currently owned by company insiders. </p><h2>Institutional Trading of Nektar Therapeutics</h2><p>Hedge funds and other institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its position in  Nektar Therapeutics by 93.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company's stock valued at $25,000 after acquiring an additional 210 shares in the last quarter.  FNY Investment Advisers LLC bought a new stake in shares of  Nektar Therapeutics in the 2nd quarter worth $39,000.  Compass Wealth Management LLC bought a new stake in shares of  Nektar Therapeutics in the 3rd quarter worth $88,000.  Bessemer Group Inc. raised its stake in shares of  Nektar Therapeutics by 1,741.2% in the third quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company's stock worth $90,000 after purchasing an additional 1,480 shares during the last quarter.  Finally, Bayforest Capital Ltd bought a new position in shares of  Nektar Therapeutics during the third quarter valued at $96,000. 75.88% of the stock is owned by hedge funds and other institutional investors. </p><h2>About Nektar Therapeutics</h2> (Get Free Report)<p>Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Nektar Therapeutics</li><li>Market Cap Calculator: How to Calculate Market Cap</li><li>3 AI Names With Big Buybacks: GEV, PSTG, and LSCC Signal Confidence</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>Western Digital’s Nasdaq-100 Entry Caps Its AI-Driven Comeback</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>Paramount Threw a Wrench in Netflix's Bid to Acquire Warner Bros.</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TktUUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Nektar Therapeutics Right Now?</h2><p>Before you consider Nektar Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.</p><p>While Nektar Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NKTR

<p>HC Wainwright raised its price target for Nektar Therapeutics (NASDAQ:NKTR) from $120.00 to $135.00 and maintained a "buy" rating. This suggests a potential upside of 167.86% from the stock's previous close. Other analysts also have positive ratings, with a consensus rating of "Moderate Buy" and an average price target of $108.83. Nektar's stock performance shows a 12-month range of $6.45 to $66.92, with recent trading at $50.40. The company reported better-than-expected earnings for the last quarter.</p>

Nektar Therapeutics (NASDAQ:NKTR) Given New $135.00 Price Target at HC Wainwright